Neuroleptic malignant syndrome: Diagnosis and management

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 20, Issue 1, 2018, Pages

  Ware, Michael R ^a   Feller, David B ^a   Hall, Karen L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; BREXPIPRAZOLE; CARIPRAZINE; CLOZAPINE; CREATINE KINASE; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT;

ARTICLE; BLOOD PRESSURE FLUCTUATION; CONSCIOUSNESS; DELPHI STUDY; HUMAN; HYPERMETABOLISM; HYPERTHERMIA; MENTAL HEALTH; MORTALITY RATE; NEUROLEPTIC MALIGNANT SYNDROME; PSYCHOMOTOR ACTIVITY; PUBLICATION; RECOGNITION; SCIENTIFIC LITERATURE; TREATMENT OUTCOME; MORTALITY; PATHOPHYSIOLOGY;

DOPAMINE AGENTS; HUMANS; NEUROLEPTIC MALIGNANT SYNDROME;

EID: 85044567710     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.17r02185     Document Type: Article

References (42)

1. Caroff SN. The neuroleptic malignant syndrome. J Clin Psychiatry. 1980;41: 79-83.
2. Keck PE, Harrison GP, Cohen BM, et al. Risk factors for neuroleptic malignant syndrome: a case-control study. Arch Gen Psychiatry. 1989;46(10): 914-918.
3. Gurrera RJ, Caroff SN, Cohen A, et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry. 2011;72(09): 1222-1228.
4. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993;77(1): 185-202.
5. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Psychopharmacol Bull. 1988;24: 25-29.
6. Rosebush P, Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry. 1989;146(6): 717-725.
7. Velamoor VR, Norman RMG, Caroff SN, et al. Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis. 1994;182(3): 168-173.
8. Gurrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry. 1999;156: 169-180.
9. Mann SC, Caroff SN, Fricchione G, et al. Central dopamine hypoactivity and the pathogenesis of neuroleptic malignant syndrome. Psychiatr Ann. 2000;30(5): 363-374.
10. Ananth J, Parameswaran S, Gunatilake S, et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry. 2004;65(4): 464-470.
11. Strawn JR, Keck PE, Caroff SN. Neuroleptic malignant syndrome: answers to 6 tough questions. Curr Psychiatr. 2008;7: 95-101.
12. Tse L, Barr AM, Scarapicchia V, et al. Neuroleptic malignant syndrome: a review from a clinically oriented perspective. Curr Neuropharmacol. 2015;13(3): 395-406.
13. Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry. 1998;155(8): 1113-1116.
14. Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Association Publishing Textbook of Psychopharmacology. 5th ed. Arlington, VA: American Psychiatric Association; 2017.
15. Murri MB, Guaglianone A, Bugliani M, et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs R D. 2015;15(1): 45-62.
16. Sarkar S, Gupta N. Drug information update: atypical antipsychotics and neuroleptic malignant syndrome: nuances and pragmatics of the association. BJPsych Bulletin. 2017;41: 211-216.
17. Strawn JR, Keck PE, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007;164(6): 870-876.
18. Stubner S, Rustenbeck E, Grohmann R, et al. Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry. 2004;37(suppl 1): S54-S64.
19. Hall KL, Taylor WH, Ware MR. Neuroleptic malignant syndrome due to olanzapine. Psychopharmacol Bull. 2001;35: 49-54.
20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013.
21. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry. 1985;142(10): 1137-1145.
22. Guze BH, Baxter LR. Neuroleptic malignant syndrome. N Engl J Med. 1985;313(3): 163-166.
23. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11): 1112-1120.
24. Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry. 1989;50: 18-25.
25. Gelenberg AJ. The catatonic syndrome. Lancet. 1976;1(7973): 1339-1341.
26. Fink M, Taylor MA. The catatonic syndrome: forgotten but not gone. Arch Gen Psychiatry. 2009;66(11): 1173-1177.
27. Koch M, Chandragiri S, Rizvi S, et al. Catatonic signs in neuroleptic malignant syndrome. Compr Psychiatry. 2000;41(1): 73-75.
28. Lee JWY. Neuroleptic-induced catatonia: clinical presentation, response to benzodiazepines, and relationship to neuroleptic malignant syndrome. J Clin Psychopharmacol. 2010;30(1): 3-10.
29. Rosebush PI, Mazurek MF. Catatonia and its treatment. Schizophr Bull. 2010;36(2): 239-242.
30. Komatsu T, Nomura T, Takami H, et al. Catatonic symptoms appearing before autonomic symptoms help distinguish neuroleptic malignant syndrome from malignant catatonia. Intern Med. 2016;55(19): 2893-2897.
31. Castillo E, Rubin R, Holsboer-Trachsler E. Clinical differentiation between lethal catatonia and neuroleptic malignant syndrome. Am J Psychiatry. 1989;146(3): 324-328.
32. Caroff SN, Mann SC, Keck PE Jr. Specific treatment of the neuroleptic malignant syndrome. Biol Psychiatry. 1998;44: 378-380.
33. Strawn JR, Keck PE. Early bicarbonate loading and dantrolene for ziprasidone/haloperidol-induced neuroleptic malignant syndrome. J Clin Psychiatry. 2006;67(4): 677.
34. Bienvenu OJ, Neufeld KJ, Needham DM. Treatment of four psychiatric emergencies in the intensive care unit. Crit Care Med. 2012;40(9): 2662-2670.
35. Francis A, Chandragiri S, Rizvi S, et al. Is lorazepam a treatment for neuroleptic malignant syndrome? CNS Spectr. 2000;5(7): 54-57.
36. Trollor JN, Sachdev PS. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust NZ J Psychiatry. 1999;33(5): 650-659.
37. Caroff SN, Mann SC, Keck PE, et al. Residual catatonic state following neuroleptic malignant syndrome. J Clin Psychopharmacol. 2000;20(2): 257-259.
38. Rosebush PI, Stewart TD, Gelenberg AJ. Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients. J Clin Psychiatry. 1989;50: 295-298.
39. Olfson M, Kroenke K, Wang S, et al. Trends in office-based mental health care provided by psychiatrists and primary care physicians. J Clin Psychiatry. 2014;75(03): 247-253.
40. Mark TL, Levit KR, Buck JA. Psychotropic drug prescriptions by medical specialty. Psychiatr Serv. 2009;60(9): 1167.
41. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166(9): 980-991.
42. Nelson JC. Adjunctive ziprasidone in major depression and the current status of adjunctive atypical antipsychotics. Am J Psychiatry. 2015;172(12): 1176-1178.